The NCPE Rapid Review of onasemnogene abeparvovec intrathecal (Itvisma®) is the first national assessment to be completed for a drug with an EU Joint Clinical Assessment (JCA). The JCA report, which includes relative effectiveness estimates derived from indirect treatment comparison methods, was used to inform this Rapid Review assessment. The JCA report complements national procedures providing a broader evidence base for the Rapid Review process and provides earlier information on comparative effectiveness for decision-making.
This is an example of how prompt application by Health Technology Developers with national processes for drugs with a JCA can facilitate the intended efficiencies of European collaboration at a national level.
The JCA Report for onasemnogene abeparvovec intrathecal (Itvisma®) was endorsed, by the EC HTA Cordination Group, on 16 July 2026. In line with the Health Technology Assessment Regulation, the European Commission will now carry out a procedural review to verify that the report has been prepared in compliance with the applicable requirements. The report will be published in a timely manner following a successful conclusion of this procedural review.